Ursprung des Netzwerks ersten Grades von J. Lynn Rutkowski
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Ossianix, Inc.
Ossianix, Inc. Pharmaceuticals: GenericHealth Technology Ossianix, Inc. develops single domain antibodies. It develops biotherapeutic products using the versatile single domain VNAR antibody from the shark and also developed highly innovative approaches to target specific cells and tissues such as the brain via the blood brain barrier and peripheral nerve via the neuromuscular junction. The company was founded by Frank S. Walshin, J. Lynn Rutkowski and Corey S. Goodman in 2011 and is headquartered in Philadelphia, PA.
5
| Holding Company | Pharmaceuticals: Generic | 5 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von J. Lynn Rutkowski
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
Lundbeck Research USA, Inc.
Lundbeck Research USA, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Research USA, Inc. develops pharmaceutical products and information to the medical community. The firm engages in the drug discovery aimed at treating central nervous system diseases by designing small molecule therapeutics. The company was founded in 1990 and is headquartered in Paramus, NJ. | Pharmaceuticals: Major | Chairman | |
EXELIXIS, INC. | Pharmaceuticals: Major | Founder | |
Renovis, Inc.
Renovis, Inc. Pharmaceuticals: MajorHealth Technology Renovis, Inc. develops pharmaceutical products. The company discovers, develops, and commercializes novel therapeutics for neurological and inflammatory diseases. It is headquartered in San Francisco, CA | Pharmaceuticals: Major | Founder | |
SAREUM HOLDINGS PLC | Miscellaneous | Director/Board Member | |
RENEURON GROUP PLC | Pharmaceuticals: Major | Director/Board Member | |
GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
Stanford University | College/University | Undergraduate Degree | |
University of Oxford | College/University | Undergraduate Degree | |
University of Cambridge | College/University | Doctorate Degree | |
Glaxo Smithkline Plc /Clinical Pharmacology Unit/ | Miscellaneous Commercial Services | Corporate Officer/Principal | |
University of London | College/University | Doctorate Degree | |
University of Strathclyde | College/University | Undergraduate Degree | |
ZEALAND PHARMA A/S | Pharmaceuticals: Major | Founder Director/Board Member | |
ReNeuron Ltd.
ReNeuron Ltd. BiotechnologyHealth Technology ReNeuron Ltd. researches and develops drugs, diagnostics, and other therapeutic products. The company was founded on May 23, 1997 and is headquartered in Bridgend, the United Kingdom. | Biotechnology | Director/Board Member | |
University College London | College/University | Doctorate Degree | |
Glaxo SmithKline Consumer Healthcare Ltd.
Glaxo SmithKline Consumer Healthcare Ltd. Medical DistributorsDistribution Services GlaxoSmithKline Consumer Healthcare manufactures and supplies over the counter drugs. It focuses on oral healthcare, over the counter medicines and nutritional healthcare products. Its brands and products include oral care (Aquafresh) to dermatology (Zovirax), with all kinds of analgesics (Panadol), gastrointestinal remedies (Tums) and smoking-cessation products (Nicoderm). The company is headquartered in Brentford, UK | Medical Distributors | Corporate Officer/Principal | |
AVACTA GROUP PLC | Miscellaneous Commercial Services | Director/Board Member | |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Private Equity Investor | |
Wyeth BioPharma
Wyeth BioPharma Pharmaceuticals: MajorHealth Technology Part of Pfizer Inc., Wyeth BioPharma is a company that develops and manufactures protein biopharmaceuticals. The company is based in Collegeville, PA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
The European Molecular Biology Laboratory | College/University | Corporate Officer/Principal | |
The National Research Council
The National Research Council Miscellaneous Commercial ServicesCommercial Services The National Research Council provides science, technology and health policy consulting and advice. The company was founded in 1916 and is headquartered in Washington, DC. | Miscellaneous Commercial Services | Chairman | |
European Molecular Biology Organization | Corporate Officer/Principal | ||
Glycom A/S
Glycom A/S BiotechnologyHealth Technology Glycom A/S engages in the development, synthesis, and commercialization of human milk oligosaccharides. It develops chemical and enzymatic technologies for synthesis of human milk oligosaccharide powders. The company was founded by Gyuala Dekany, Mark von Itzstein, Joachim Erich Thiem, Arnold Stutz, and Inge Lundt on March 22, 2005 and is headquartered in Horsholm, Denmark. | Biotechnology | Founder | |
Ysios Capital Partners SGEIC SA
Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital Partners SGEIC SA (Ysios Capital) is a venture capital firm founded in 2007 by Joël Jean Pierre Jean-Mairet, Julia Salaverría Monfort and Josep Lluís Sanfeliu Benet. The firm is headquartered in San Sabastian, Spain with additional office in Barcelona. | Investment Managers | Private Equity Investor | |
Covagen AG
Covagen AG BiotechnologyHealth Technology Covagen AG engages in the research in as well as development, production, and distribution of pharmaceutical and diagnostic products and technologies. The company was founded by Julian Bertschinger and Dragan Grabulovski in 2007 and is headquartered in Zug, Switzerland. | Biotechnology | Chairman | |
venBio Partners LLC
venBio Partners LLC Investment ManagersFinance venBio Partners LLC (venBio) is a venture capital subsidiary of Venbio Partners LP founded in 2009 by Adelman robert and Goodman corey. The firm is headquartered in San Francisco, California. | Investment Managers | Founder | |
IMMUNOVIA AB | Pharmaceuticals: Major | Chairman | |
Lundbeck Pharma A/S
Lundbeck Pharma A/S Medical DistributorsDistribution Services Lundbeck Pharma A/S markets and sells medicines within Central Nervous System. It specializes in various illnesses and conditions such as depression, Schizophrenia, anxiety, alcohol dependence, and Parkinson's and Alzheimer's diseases. The company was founded on January 1, 1988 and is headquartered in Valby, Denmark. | Medical Distributors | General Counsel | |
Second Genome, Inc.
Second Genome, Inc. BiotechnologyHealth Technology Second Genome, Inc. develops microbiome-based therapeutic products. It offers phyclochip community, 16S sequencing community analysis, whole metagenomic profiling, nucleic acid isolation, inferred function and custom informatics services. The company was founded in 2009 by Corey S. Goodman, Janet A. Warrington, Todd Z. DeSantis, John Hulls and Gary Andersen and is headquartered in South San Francisco, CA. | Biotechnology | Founder | |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Founder | |
Iksuda Therapeutics Ltd.
Iksuda Therapeutics Ltd. BiotechnologyHealth Technology Iksuda Therapeutics Ltd. operates as a biotechnology company which specializes in the development of next generation biotherapeutics. It creates new generation biological therapeutics through advanced glycosylation and conjugation technologies. The company has core expertise in protein/peptide fictionalization and glycosylation technologies, imparting improved pharmacokinetic properties to a broader range of biological therapeutics. It was founded by David John Simpson and Andrew Watts on November 21, 2007 and is headquartered in Newcastle upon Tyne, the United Kingdom. | Biotechnology | Director/Board Member | |
Prexton Therapeutics SA
Prexton Therapeutics SA Pharmaceuticals: MajorHealth Technology Prexton Therapeutics SA operates as a biopharmaceutical company which develops novel therapeutic compounds as a new treatment for Parkinson’s disease and other brain disorders. The company was founded by Francois Conquet in 2012 and is headquartered in Geneva, Switzerland. | Pharmaceuticals: Major | Founder | |
Biotech Research & Innovation Centre | Chairman | ||
InnovationsFonden
InnovationsFonden Investment ManagersFinance InnovationsFonden provides investment services. It invests in entrepreneurs, researchers, and businesses. The company was founded on January 4, 2005 and is headquartered in Copenhagen, Denmark. | Investment Managers | Chief Executive Officer | |
Edvince AB
Edvince AB BiotechnologyHealth Technology Edvince AB engages in clinical research and development services. It operates as a biotech company that focuses on a new form of emergency treatment for stroke. The company was founded by Lars Ingvar Herbert Edvinsson in 2003 and is headquartered in Lund, Sweden. | Biotechnology | Chairman | |
BliNK Biomedical SAS
BliNK Biomedical SAS BiotechnologyHealth Technology BliNK Biomedical SAS is a French company that specializes in cutting-edge technology for identifying rare antibody-secreting cells from humans and other species. The company is based in Marseille, France. The company's technology is based on validated platforms, isaac and vivascreen, which provide a highly efficient and deep mining process. The CEO of the company is Jack Elands. | Biotechnology | Director/Board Member | |
Gammadelta Therapeutics Ltd.
Gammadelta Therapeutics Ltd. BiotechnologyHealth Technology Gammadelta Therapeutics Ltd. is developing the potential of gamma delta (?d) cells to create improved immunotherapy of cancer and other serious diseases. The company was founded by Raj Mehta in 2016 and is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member | |
Avacta Life Sciences Ltd.
Avacta Life Sciences Ltd. Pharmaceuticals: MajorHealth Technology Avacta Life Sciences Ltd. provides powerful reagents for research and diagnostics. The company is headquartered in Wetherby, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
MONSENSO A/S | Internet Software/Services | Director/Board Member | |
SCANDION ONCOLOGY A/S | Pharmaceuticals: Major | Chairman | |
The Club Cricket Organisation Ltd. | Director/Board Member | ||
Ossianix Uk Ltd. | Director/Board Member | ||
VectorY BV
VectorY BV Miscellaneous Commercial ServicesCommercial Services VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation. | Miscellaneous Commercial Services | Director/Board Member | |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Biotechnology | Director/Board Member |
Statistik
International
Vereinigtes Königreich | 21 |
Vereinigte Staaten | 11 |
Dänemark | 8 |
Niederlande | 5 |
Deutschland | 3 |
Sektoral
Health Technology | 27 |
Consumer Services | 8 |
Commercial Services | 6 |
Finance | 5 |
Distribution Services | 3 |
Operativ
Director/Board Member | 40 |
Chairman | 20 |
Corporate Officer/Principal | 20 |
Founder | 17 |
Independent Dir/Board Member | 8 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Corey Goodman | 35 |
Peter Andersen | 26 |
Michael Owen | 20 |
Frank S. Walsh | 8 |
Steve Moore | 4 |
- Börse
- Insiders
- J. Lynn Rutkowski
- Unternehmensverbindungen